Skip to main content
. Author manuscript; available in PMC: 2023 Oct 4.
Published in final edited form as: J Am Coll Cardiol. 2022 Oct 4;80(14):1287–1298. doi: 10.1016/j.jacc.2022.07.027

FIGURE 2. Cumulative Incidence of MACE Stratified by rs3798220-C Carrier Status.

FIGURE 2

Among 12,815 genotyped participants, 406 (3.2%) were carriers of the rs3798220-C allele (404 heterozygotes, 2 homozygotes, considered as a single carrier group). For rs3798220-C carriers (red line) vs noncarriers (blue line), we estimated the cumulative incidence of major adverse cardiovascular events (MACE) in the aspirin and placebo groups. (A) A higher cumulative incidence of MACE was observed in rs3798220-C carriers in the placebo arm of the trial. (B) However, this risk was attenuated in the aspirin arm, with a lower cumulative incidence of MACE observed in rs3798220-C carriers than noncarriers.